Compare Logitech International SA (LOGI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs State Street SPDR S&P Biotech ETF — how do they compare? Logitech International SA trades at $100.98 (market cap $14.96B), while State Street SPDR S&P Biotech ETF trades at $159.63. The key difference: Logitech International SA pays a 1.64% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Logitech International SA nearer its low. Which is the better fit depends on your goals.
| LOGI | XBI | |
|---|---|---|
Market Cap | $14.96B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $126.69 | $164.28 |
52-Week Low | $85.84 | $86.92 |
Enterprise Value | $13.30B | — |
Dividend Yield | 1.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $104.87, down 1.37% on the day, with a neutral technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat estimates with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand, though a key supplier shutdown clouds near-term outlook. Fundamentals show strong profitability with a 16.28% net margin and 35.29% ROE, while valuation metrics like a P/E of 19.03 appear reasonable. The stock faces resistance near $109, with support at $104.
The outlook is cautiously optimistic given solid earnings momentum and margin expansion, but supply chain disruptions pose a near-term risk. Upside to the $109.75 consensus price target offers potential, though investor sentiment is divided amid operational uncertainties. Key risks include supplier dependency and competitive pressures in the tech peripherals market.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
